Department of Pharmacology, Kitasato University School of Medicine and Department of Molecular Pharmacology, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa 252-0374, Japan.
Department of Pharmacology, Kitasato University School of Medicine and Department of Molecular Pharmacology, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa 252-0374, Japan.
Trends Pharmacol Sci. 2019 Jan;40(1):11-21. doi: 10.1016/j.tips.2018.11.003. Epub 2018 Nov 28.
Migraine is a severe neurological disorder in which calcitonin gene-related peptide (CGRP) is a key molecule in pathophysiology. Neuronal system-derived CGRP enhances neovascularization in several important pathological conditions and sends a cue to the vascular system. In 2018, the FDA approved erenumab and fremanezumab, antibodies against CGRP receptor and CGRP, as the first new class of drugs for migraine. Treatment of migraine with these antibodies requires great care because neovascularization-related adverse effects may be induced in some patients. Here, we focus on enhancement of neovascularization by CGRP and discuss possible adverse effects resulting from blocking neovascularization. We also suggest that CGRP antibodies may also be used as novel antitumor agents by suppressing tumor-associated angiogenesis.
偏头痛是一种严重的神经系统疾病，降钙素基因相关肽（CGRP）是其病理生理学中的关键分子。源自神经元系统的 CGRP 可增强几种重要病理状况下的新生血管形成，并向血管系统发出信号。2018 年，FDA 批准了针对 CGRP 受体和 CGRP 的单克隆抗体 erenumab 和 fremanezumab，作为偏头痛的首个新型药物类别。使用这些抗体治疗偏头痛需要格外小心，因为可能会在某些患者中引起与新生血管形成相关的不良反应。在这里，我们重点关注 CGRP 对新生血管形成的增强作用，并讨论阻断新生血管形成可能导致的不良反应。我们还提出，CGRP 抗体也可以通过抑制肿瘤相关血管生成而被用作新型抗肿瘤药物。
